CC
GPCR icon

Casdin Capital’s Structure Therapeutics GPCR Stock Holding History

Casdin Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.1M Hold
1,175,000
– – 3.16% 7
2026
Q1 		$56.6M Hold
1,175,000
– – 4.29% 7
2025
Q4 		$81.7M Sell
1,175,000
-380,000
-24% -$15.5M 5.08% 6
2025
Q3 		$43.5M Buy
1,555,000
+330,000
+27% +$6.57M 3.63% 8
2025
Q2 		$25.4M Buy
1,225,000
+525,000
+75% +$11.5M 2.31% 10
2025
Q1 		$12.1M Hold
700,000
– – 0.99% 18
2024
Q4 		$19M Hold
700,000
– – 1.26% 18
2024
Q3 		$30.7M Hold
700,000
– – 2.05% 12
2024
Q2 		$27.5M Sell
700,000
-416,867
-37% -$17.1M 2.1% 13
2024
Q1 		$47.9M Buy
1,116,867
+25,000
+2% +$1.05M 3.56% 9
2023
Q4 		$44.5M Sell
1,091,867
-166,299
-13% -$9.53M 4.37% 5
2023
Q3 		$62M Buy
1,258,166
+261,149
+26% +$8.42M 6.86% 4
2023
Q2 		$41.4M Buy
997,017
+320,000
+47% +$8.97M 3.62% 10
2023
Q1 		$16.1M Buy
+677,017
New +$15.9M 1.33% 23

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Casdin Capital's GPCR Position: Q2 2026 in Review

Casdin Capital held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 1,175,000 shares worth $63.1M. The position accounts for 3.16% of the portfolio, ranked #7.

Casdin Capital first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $81.7M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Casdin Capital held 1,175,000 shares of Structure Therapeutics worth $63.1M as of Q2 2026.
  • Casdin Capital left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up 3.16% of Casdin Capital's portfolio in Q2 2026, its #7 holding.
  • Casdin Capital first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Casdin Capital's Structure Therapeutics position peaked at $81.7M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.